Incyte Genomics, Inc. (INCY) Posts Narrower than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $126.75 -0.98%
EPS Growth %: -225.2%
Financial Fact:
Total costs and expenses: 247.18M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -225.2%
Financial Fact:
Total costs and expenses: 247.18M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Incyte Genomics, Inc. (NASDAQ: INCY) reported Q3 loss of ($0.42), $0.03 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.54 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
